Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB's double-blind, randomised Recover study showed that treatment with Neupro (rotigotine) improved motor function, sleep and non-motor symptoms, compared to placebo, improving quality of life for people with Parkinson's disease (PD).
Subscribe to our email newsletter
UCB claims that the Recover study is the first large-scale trial to investigate early morning motor function and sleep as coprimary outcome measures in Parkinson’s disease (PD).
Data from the study showed that treatment with rotigotine improved both early morning motor function and nocturnal sleep disturbance compared with placebo.
Additionally, improvements were also seen with rotigotine in secondary and additional exploratory outcome measures related to sleep quality, pain, depression and activities of daily living.
University of Goettingen and Paracelsus-Elena Klinik, Kassel, Germany Neurology professor and Recover study investigator Claudia Trenkwalder said that the Recover study demonstrated benefits with rotigotine on each of these outcomes.
"It also demonstrated the clinical benefits of continuous rotigotine delivery, as efficacy was maintained throughout the night and into the next morning, and significantly improved the start of the new day, one of the most troubling times for PD patients,Trenkwalder said.